Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Betta Pharma Licenses Lung Cancer Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Betta Pharma Licenses Lung Cancer Drug

D-0316 is a third-generation EGFR-T790M tyrosine kinase inhibitor in Phase I development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

InventisBio has signed a collaboration agreement with Betta Pharma under which InventisBio will out-license D-0316’s right in China to Betta Pharma for development. Betta Pharma will have the exclusive commercialization rights of D-0316 product in China.

D-0316 is a third-generation EGFR-T790M tyrosine kinase inhibitor mainly used for the treatment of EGFR-mutant non-small cell lung cancer. The drug is currently in Phase I development in China. Betta Pharma will pay 230 million RMB in upfront and R&D milestones. InventisBio is eligible to receive sales milestones and royalties on sales.

Dr. Yaolin Wang, chairman and chief executive officer of InventisBio, said, “We are excited to work with Betta Pharma, a leader in oncology drug in China. Working together, we will speed up the development and market approval of D-0316 to meet the growing needs of lung cancer patients.”

Dr. Lieming Ding, chairman and chief executive officer of Betta Pharma, said, “We are pleased to work with InventisBio, a leader in oncology drug innovation. The collaboration will broaden the coverage of Betta Pharma’s capabilities in lung cancer treatment.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics